THE BALANCEhttps://thebalance.clinic/resources/research/mental-health-evidence-2026-q1/

Swiss roots. International expertise. Personal care, delivered with privacy and discretion.

THE BALANCE

Private admissions

Let’s talk about your next step.

Speak with our admissions team about treatment for you or someone you care about.

Privacy and discretion from the first conversation.

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager
Abdullah Boulad, Founder & CEO

Prefer to speak with our founder?

Abdullah Boulad · Swiss entrepreneur · Founder & CEO

Clinical resource

THE BALANCE Quarterly Evidence Briefing: Q1 2026: Faster Care, Harder Questions

A retrospective Q1 2026 briefing on European drug signals, treatment quality, rapid depression interventions, and confidential access. The figures distinguish newly released evidence from the periods measured.

Clinically reviewed byDr. Sarah Boss, MD
Stone residence with a swimming pool, lawn and palm trees

Faster treatment and easier access dominated several developments in the first quarter of 2026. The evidence also asked a harder question: what happens after contact? European drug monitoring, international care research, depression trials, and Dubai’s new guidance service each revealed a different part of the pathway. None supplied a single recovery score.

Key findings

Nearly +41%, nearly +22%, and -16%: changes in ketamine, cocaine, and MDMA wastewater loads in the respective paired-city comparisons between 2024 and 2025. Released March 18, these were not Q1 consumption observations. [1]

47.1%: person-disorder cases meeting stricter structural care criteria among those already receiving minimally adequate treatment in a February analysis. Clinical recovery was not measured. [2]

34 versus 144 participants: the sizes of two separate psychedelic depression trials with different primary findings and endpoints. Their results cannot establish which intervention is better. [3] [4]

March 13: launch of Dubai’s Itma’en confidential guidance service. The announcement describes access, not a completed outcome evaluation. [6]

The quarter’s release calendar

Newly released evidence and its observation period
ReleaseDevelopmentWhat was measured
February 16DMT depression trial2021 to 2022 trial with blinded and open-label phases [3]
February 24Treatment-quality analysisSurveys conducted in 2001 to 2019 [2]
March 3Accelerated TMS trialSpecified stimulation schedules [5]
March 13Itma’en launchA new service route, not outcomes [6]
March 18EUDA wastewater reportSampling in participating locations during 2025 [1]
March 18German EPISODE trialSix-week response and other trial outcomes [4]

Europe’s drug signals did not all move upward

Changes in measured wastewater drug loads, 2024 to 2025Ketamine nearly plus 41 percent, cocaine nearly plus 22 percent, and MDMA minus 16 percent. Each uses a different eligible paired-city set. These are not changes in the percentage of people using drugs.Changes in reported loads; March 18, 2026 releaseKetaminenearly +41%Cocainenearly +22%MDMA-16%-20%0+20%+40%

Approximate changes are reproduced as reported. They do not identify occupation, wealth, or addiction prevalence. Source: EUDA and SCORE. [1]

The project covered 115 European cities. Within the relevant paired comparisons, 40 of 66 recorded increased ketamine residues, 48 of 85 increased cocaine residues, and 48 of 78 decreased MDMA residues.

These are monitoring locations, not patients. A city-level change can help identify questions for services without establishing what any individual resident uses.

For coverage of financial centers and affluent communities, the occupational angle needs separate evidence. Wastewater cannot identify bankers or wealthy households. The MDMA decline also belongs in the story; selecting only increases would exaggerate the source’s conclusion.

Enough appointments did not establish appropriate care

The February analysis examined 2,313 person-disorder cases among 1,119 people already receiving minimally adequate treatment. Its stricter criteria concerned features of delivered care, not whether patients recovered. [2]

One person could contribute more than one disorder case. Appropriate care for one condition did not automatically establish the same for another.

For a private patient, a full timetable can look comprehensive. Ask why its components address the assessed needs and how the plan changes when progress is insufficient. Contact volume alone cannot supply that answer.

Four stages to keep separate
StageQuestion
AccessDid the person reach assessment or treatment?
AdequacyWas a defined minimum course received?
QualityDid its content fit the clinical circumstances?
OutcomeDid health or functioning improve and remain improved?

Rapid depression studies produced different answers

The DMT trial randomized 34 adults. At two weeks, the active-treatment group had a greater reduction in clinician-rated depression than placebo: a MADRS difference of -7.35 points, with a 95% confidence interval from -13.62 to -1.08. Later open-label observation did not preserve the same controlled comparison. [3]

Germany’s EPISODE trial randomized 144 participants. Six-week response rates were 17.0%, 12.5%, and 10.6% across the higher-dose, lower-dose, and active-placebo groups. The first prespecified comparison was not significant. Secondary findings retained exploratory status. [4]

EPISODE six-week responseHigher-dose 17 percent, lower-dose 12.5 percent, active placebo 10.6 percent. Primary superiority comparison not significant. Bars start at zero on a 20 percent scale.Six-week response; primary comparison inconclusiveHigher-dose group17.0%Lower-dose group12.5%Active placebo10.6%01020%

Numerical differences do not replace the statistical comparison. These rates cannot be ranked against the DMT trial’s score change. Source: EPISODE. [4]

A family needs the evidence for the specific treatment package, including supervision, population, and follow-up. A short administration session does not establish a short complete pathway or general authorization to receive the intervention.

A shorter stimulation schedule still needed an active comparison

The March H1-coil trial randomized 104 adults to accelerated or standard schedules. Mean six-week score reductions were 19.02 and 19.79 points, and the analysis met its prespecified noninferiority criterion. [5]

That supports a defined schedule comparison, not superiority over every alternative. The concentrated initial phase still had a continuing treatment component.

For someone traveling, assessment, subsequent visits, tolerability, and follow-up belong in the time calculation. Convenience may matter without proving additional clinical benefit.

Dubai made confidential first contact a visible priority

Itma’en was announced as a free confidential mental-well-being guidance route for citizens, residents, and visitors, with referral for further assessment where needed. [6]

The relevant evaluation follows the initial conversation. Did the person obtain appropriate care, and what changed? A launch announcement cannot provide those results in advance.

Visitor access is relevant to internationally mobile people, but the announcement does not identify wealthy users or quantify professional-reputation concerns.

Regional relevance without an invented ranking

Scope of the selected Q1 evidence
MarketRelevant question
UK and GermanySpecific treatment trials, not nationwide recovery
Netherlands, Switzerland, Western EuropeMonitoring locations and care decisions, not wealthy-user estimates
USATreatment-quality and comparison questions, without a new prevalence claim here
UAEDubai’s new access route, not all-emirate outcomes
Saudi Arabia and other GCC countriesNo new comparable Q1 outcome series established in this selective briefing

Uneven coverage does not imply that an unlisted country had no developments. It means the briefing does not substitute a weak or incompatible statistic merely to fill a geographic slot.

What changes for a family choosing care?

Ask what was studied, what is offered, and which result is being promised. Evidence for one treatment component is not automatically a provider’s own outcome.

Then examine the transition home. Who receives the history, reviews medication, and responds if symptoms change? A referral suggestion is not an accepted handover.

The ability to travel or buy rapid access expands possibilities without converting a small short trial into a long-term guarantee. A useful plan explains clinical fit, review points, and uncertainty.

The bottom line

Q1’s strongest theme was the distance between speed, access, and outcomes. The developments were meaningful, but their numbers measured different things. Families and journalists should keep the full pathway in view rather than let the fastest or largest figure define success.

For journalists

Reporting window: January 1 through March 31, 2026. This retrospective was prepared in October 2026 and is not backdated.

Key contrast: drug signals diverged, treatment-quality criteria differed from recovery, and rapid-treatment trials produced distinct findings.

Suggested attribution: THE BALANCE retrospective analysis of Q1 releases and cited clinical studies.

Methodology and sources

This selective narrative briefing uses release dates within Q1 while retaining the underlying observation periods. It is not a systematic review or an original HNW survey. Later-quarter findings are not presented as Q1 news. Charts reproduce reported values without new causal estimates.

  1. EUDA and SCORE. Wastewater findings. March 18, 2026; observations 2025.
  2. Kazdin and colleagues. Adequate treatment and effective coverage. February 24, 2026.
  3. Erritzoe and colleagues. DMT depression trial. February 16, 2026.
  4. Mertens and colleagues. EPISODE trial. March 18, 2026.
  5. Hanlon and colleagues. H1-coil stimulation trial. March 3, 2026.
  6. Dubai Health and partners. Itma’en announcement. March 13, 2026.
What this includes
01

Clinical context

Clear information is framed around complex and co-occurring presentations.

02

Individual factors

Assessment remains essential because needs and risks differ from person to person.

03

Next steps

A confidential conversation can help clarify the most appropriate route forward.

Not sure where the situation fits?

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager

A confidential first conversation can help clarify the presentation and whether our setting is appropriate.

THE BALANCE
A PLACE TO BEGIN

Ask about our care